SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

July 05, 2012 11:06 ET

Implant Sciences Described as "An Attractive Pure-Play in Explosives Detection" in Gene Marcial's Blog on Forbes.com

WILMINGTON, MA--(Marketwire - Jul 5, 2012) - Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has been featured in Gene Marcial's 'Street Beat' blog on Forbes.com. Forbes.com describes itself as the "home page for the world's business leaders and the leading business news source in the world." The posting, headlined "Implant Sciences: Little Known Pure-Play On Bomb Detection Systems Starting To Attract Investor Attention," can be viewed by clicking on the link http://blogs.forbes.com/genemarcial/

Gene Marcial, who many readers know from his 28 years as author of Business Week's "Inside Wall Street" column, describes Implant Sciences as "a pure-play whose unique, patented technologies have started to stir investor interest." This assessment is supported by comments from Rob Goldman, analyst at Goldman Small Cap Research, who is quoted in the posting, "With demand for its product starting to mount, Implant has become an attractive pure play in explosives-detection."

Also quoted is Gregory MacArthur, president of investment consulting firm ViewPoint2000, who states, "Implant's technologies... have a broader market and greater demand than those of security metal detectors." Later in the posting Gene Marcial writes, "With Implant's strong growth prospects, says MacArthur, the stock offers great upside potential over the next six to 12 months. He believes the stock is worth $3 to $4 a share."

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 benchtop explosives and narcotics trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risk that we will be required to repay all of our indebtedness to our secured lender, DMRJ Group, by September 30, 2012; that if we are unable to satisfy our obligations to DMRJ and to raise additional capital to fund operations, DMRJ may seize our assets and our business may fail; the risk that we continue to incur substantial operating losses and may never be profitable; the risk that liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; the risk that we may not be able to retain our management and key employees or to identify, hire and retain additional personnel as needed; the risks that we may not be able to enforce our patent and other intellectual property rights or operate without infringing on the proprietary rights of others; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:
    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact